$11.030
-0.967 (-8.77%)Zum Schluss
ANL-News
ANL-Events
Adlai Nortye Announces Clinical Trial Collaboration with Eli Lilly and Merck KGaA
Adlai Nortye (ANL) announced clinical trial collaboration and supply agreements, or CTCSAs, with Eli Lilly (LLY) and Merck KGaA (MKGAF) for the anti-EGFR antibody cetuximab. These agreements will support Adlai Nortye's ongoing Phase I trial evaluating AN4035, a pan-RAS inhibitor-based ADC, both as monotherapy and in combination with cetuximab, in CEACAM5-enriched RAS-addicted solid tumors. Adlai Nortye is the sponsor of the trial. Lilly will supply cetuximab at no cost for the U.S. clinical trial sites. Merck KGaA, Darmstadt, Germany will supply cetuximab at no cost for the Australia and China clinical trial sites.
Adlai Nortye Appoints Dr. Liu as Head of Investor Relations
Adlai Nortye Group announced the appointment of Christopher Liu, PharmD, as Head of Investor Relations and Public Relations. Dr. Liu brings nearly a decade of equity research experience.
Adlai Nortye Initiates Global Phase I Trial of AN4035 in Australia
Adlai Nortye announced that the first patient has been dosed with AN4035 in Australia, initiating the global Phase I trial in patients with CEACAM5-enriched RAS-addicted solid tumors. The company also received a "Study-May-Proceed" letter from the FDA on its investigational new drug application, clearing the path to expand the trial into the United States.
Adlai Nortye Submits CTN for AN4035 Clinical Trial
Adlai Nortye announced that it has submitted a clinical trial notification, or CTN, to Australia's Therapeutic Goods Administration, or TGA, and received approval from the Human Research Ethics Committee, or HREC, to commence its phase I clinical trial evaluating AN4035, a CEACAM5-targeting, pan-RAS inhibitor-based antibody drug conjugate for the treatment of CEACAM5-enriched RAS-addicted solid tumors.
Adlai Nortye Doses First Patient in AN9025 Trial in the US
Adlai Nortye announced that the first patient has been dosed in the United States in the intermittent weekly dosing arm of the ongoing Phase 1 clinical trial of AN9025, a pan-RAS inhibitor.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.